Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13341MR)

This product GTTS-WQ13341MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ13341MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ897MR IVTScrip™ mRNA-Anti-PDCD1, ABBV-181(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-181
GTTS-WQ10669MR IVTScrip™ mRNA-Anti-TNFSF13B, LymphoStat-B(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LymphoStat-B
GTTS-WQ14250MR IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RG-7116
GTTS-WQ4696MR IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986168
GTTS-WQ652MR IVTScrip™ mRNA-Anti-AOC3, 8c10(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 8c10
GTTS-WQ917MR IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-221
GTTS-WQ14917MR IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ9109MR IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMGN242
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW